MYRIAD GENETICS, INC. Increase (Decrease) in Contract with Customer, Liability
MYRIAD GENETICS, INC. (MYGN) reported Increase (Decrease) in Contract with Customer, Liability of $100.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2024-05-08
- MYRIAD GENETICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was $100.00K, a 0.00% change year-over-year.
- MYRIAD GENETICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was -$400.00K.
- MYRIAD GENETICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was $100.00K.
- MYRIAD GENETICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was $0.00.
- MYRIAD GENETICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$200.00K.
- MYRIAD GENETICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$5.00M.
- MYRIAD GENETICS, INC. increase (decrease) in contract with customer, liability for fiscal 2021 was -$26.60M.
- MYRIAD GENETICS, INC. increase (decrease) in contract with customer, liability for fiscal 2020 was $30.70M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2024-03-31 | $100.00K 10-Q · filed 2024-05-08 | -$300.00K derived: sum of 2 quarters · filed 2024-05-08 | -$200.00K derived: sum of 3 quarters · filed 2024-05-08 | -$200.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$300.00K derived: sum of 2 quarters · filed 2024-02-28 | -$300.00K derived: sum of 3 quarters · filed 2024-02-28 | -$200.00K 10-K · filed 2024-02-28 |
| 2023-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $100.00K derived: sum of 2 quarters · filed 2023-11-07 | $200.00K 10-Q · filed 2023-11-07 | $100.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $100.00K 10-Q · filed 2023-08-04 | $0.00 derived: sum of 3 quarters · filed 2024-05-08 | $0.00 derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2024-05-08 | $0.00 derived: sum of 3 quarters · filed 2024-05-08 | -$400.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$100.00K derived: sum of 2 quarters · filed 2024-02-28 | -$500.00K derived: sum of 3 quarters · filed 2024-02-28 | -$5.00M 10-K · filed 2024-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$400.00K derived: sum of 2 quarters · filed 2023-11-07 | -$4.90M 10-Q · filed 2023-11-07 | -$11.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$4.90M 10-Q · filed 2023-08-04 | -$11.10M derived: sum of 3 quarters · filed 2024-02-28 | -$22.30M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$4.50M 10-Q · filed 2023-05-04 | -$10.70M derived: sum of 2 quarters · filed 2024-02-28 | -$21.90M derived: sum of 3 quarters · filed 2024-02-28 | -$29.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$17.40M derived: sum of 2 quarters · filed 2024-02-28 | -$25.00M derived: sum of 3 quarters · filed 2024-02-28 | -$26.60M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$11.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$18.80M derived: sum of 2 quarters · filed 2022-11-02 | -$20.40M 10-Q · filed 2022-11-02 | -$20.00M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$7.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$9.20M 10-Q · filed 2022-08-05 | -$8.80M derived: sum of 3 quarters · filed 2023-03-01 | -$9.40M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$1.60M 10-Q · filed 2022-05-06 | -$1.20M derived: sum of 2 quarters · filed 2023-03-01 | -$1.80M derived: sum of 3 quarters · filed 2023-03-01 | $27.10M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $400.00K derived: 10-K 6 month − 10-Q 3 month · filed 2023-03-01 | -$200.00K 10-K · filed 2023-03-01 | $28.70M derived: sum of 3 quarters · filed 2023-03-01 | $28.90M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-09-30 | -$600.00K 10-Q · filed 2020-11-09 | $28.30M derived: sum of 2 quarters · filed 2021-08-04 | $28.50M 10-Q · filed 2021-11-04 | $30.10M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-06-30 | $28.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $29.10M 10-Q · filed 2021-08-04 | $30.70M derived: sum of 3 quarters · filed 2021-08-04 | $30.70M 10-K · filed 2023-03-01 |
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-05 | $1.80M derived: sum of 2 quarters · filed 2021-05-05 | $1.80M 10-Q · filed 2020-05-06 | $1.70M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-07 | $1.60M 10-Q · filed 2020-02-07 | $1.50M derived: sum of 3 quarters · filed 2022-02-25 | $1.40M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | -$100.00K derived: sum of 2 quarters · filed 2022-02-25 | -$200.00K derived: sum of 3 quarters · filed 2022-02-25 | -$300.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-06-30 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$200.00K derived: sum of 2 quarters · filed 2022-02-25 | -$300.00K derived: sum of 3 quarters · filed 2022-02-25 | -$500.00K 10-K · filed 2022-02-25 |
| 2019-03-31 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-06 | -$200.00K derived: sum of 2 quarters · filed 2020-05-06 | -$400.00K 10-Q · filed 2020-05-06 | -$400.00K derived: sum of 4 quarters · filed 2021-03-16 |
| 2018-12-31 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-07 | -$300.00K 10-Q · filed 2020-02-07 | -$300.00K derived: sum of 3 quarters · filed 2021-03-16 | -$1.10M derived: sum of 4 quarters · filed 2021-03-16 |
| 2018-09-30 | -$200.00K 10-Q · filed 2019-11-06 | -$200.00K derived: sum of 2 quarters · filed 2021-03-16 | -$1.00M derived: sum of 3 quarters · filed 2021-03-16 | -$900.00K derived: sum of 4 quarters · filed 2021-03-16 |
| 2018-06-30 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2021-03-16 | -$800.00K derived: sum of 2 quarters · filed 2021-03-16 | -$700.00K derived: sum of 3 quarters · filed 2021-03-16 | -$100.00K 10-KT · filed 2021-03-16 |
| 2018-03-31 | -$800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-08 | -$700.00K derived: sum of 2 quarters · filed 2019-05-08 | -$100.00K 10-Q · filed 2019-05-08 | |
| 2017-12-31 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-06 | $700.00K 10-Q · filed 2019-02-06 | ||
| 2017-09-30 | $600.00K 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $900.00K 10-K · filed 2019-08-13 | |||
| 2016-06-30 | -$200.00K 10-K · filed 2018-08-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |